Search results
Search for "depression" in Full Text gives 33 result(s) in Beilstein Journal of Organic Chemistry.
Photomechanochemistry: harnessing mechanical forces to enhance photochemical reactions
- Francesco Mele,
- Ana M. Constantin,
- Andrea Porcheddu,
- Raimondo Maggi,
- Giovanni Maestri,
- Nicola Della Ca’ and
- Luca Capaldo
Beilstein J. Org. Chem. 2025, 21, 458–472, doi:10.3762/bjoc.21.33
- of organic solvents [34] required for light-mediated transformations including on- and in-water approaches [35][36][37], the use of supercritical CO2 as solvent [38], and the melting point depression strategy [39]. However, a more drastic option would be to remove the solvent: no solvent is the best
Graphical Abstract
Figure 1: The Grotthuss–Draper, Einstein–Stark, and Beer–Lambert laws. T: transmittance; ε: molar attenuation...
Figure 2: The benefits of merging photochemistry with mechanochemical setups (top). Most common setups for ph...
Scheme 1: Mechanochemically triggered pedal-like motion in solid-state [2 + 2] photochemical cycloaddition fo...
Scheme 2: Mechanically promoted [2 + 2] photodimerization of trans-1,2-bis(4-pyridyl)ethylene (2.1) via supra...
Scheme 3: Photo-thermo-mechanosynthesis of quinolines [65].
Scheme 4: Study of the mechanically assisted [2 + 2] photodimerization of chalcone [66].
Scheme 5: Liquid-assisted vortex grinding (LAVG) for the synthesis of [2.2]paracyclophane [68].
Scheme 6: Photomechanochemical approach for the riboflavin tetraacetate-catalyzed photocatalytic oxidation of...
Scheme 7: Photomechanochemical oxidation of 1,2-diphenylethyne to benzil. The photo in Scheme 7 was republished with ...
Scheme 8: Photomechanochemical borylation of aryldiazonium salts. The photo in Scheme 8 was reproduced from [72] (© 2017 ...
Scheme 9: Photomechanochemical control over stereoselectivity in the [2 + 2] dimerization of acenaphthylene. ...
Scheme 10: Photomechanochemical synthesis of polyaromatic compounds using UV light. The photo in Scheme 10 was reproduc...
Scheme 11: Mechanically assisted photocatalytic reactions: A) atom-transfer-radical addition, B) pinacol coupl...
Scheme 12: Use of mechanoluminescent materials as photon sources for photomechanochemistry. SAOED: SrAl2O4:Eu2+...
Figure 3: SWOT (strengths, weaknesses, opportunities, threats) analysis of photomechanochemistry.
Multicomponent reactions driving the discovery and optimization of agents targeting central nervous system pathologies
- Lucía Campos-Prieto,
- Aitor García-Rey,
- Eddy Sotelo and
- Ana Mallo-Abreu
Beilstein J. Org. Chem. 2024, 20, 3151–3173, doi:10.3762/bjoc.20.261
- rapid generation of chemical libraries with high diversity in a time-efficient and environmentally sustainable manner. In this review, we focus on central nervous system (CNS) disorders, particularly Alzheimer's disease, Parkinson's disease, schizophrenia, depression, and epilepsy, where MCRs have
- to the authors whose important contributions may not be included. By concentrating on these pivotal studies, we strive to offer a clear and concise perspective on current research trends and breakthroughs in this field. Keywords: Alzheimer; depression; epilepsy; multicomponent reactions; Parkinson
- identified: Alzheimer’s disease, Parkinson’s disease, depression, schizophrenia, and epilepsy. Our goal is not to provide a comprehensive survey but rather to spotlight key studies that address significant CNS disorders, pertinent drug targets, and various MCR methodologies. We have thoughtfully selected
Graphical Abstract
Figure 1: Classical MCRs.
Figure 2: Different scaffolds that can be formed with the Ugi adduct.
Scheme 1: Oxoindole-β-lactam core produced in a U4C-3CR.
Figure 3: Most active oxoindole-β-lactam compounds developed by Brãndao et al. [33].
Scheme 2: Ugi-azide synthesis of benzofuran, pyrazole and tetrazole hybrids.
Figure 4: The most promising hybrids synthesized via the Ugi-azide multicomponent reaction reported by Kushwa...
Scheme 3: Four-component Ugi reaction for the synthesis of novel antioxidant compounds.
Figure 5: Most potent antioxidant compounds obtained through the Ugi four-component reaction developed by Pac...
Scheme 4: Four-component Ugi reaction to synthesize β-amiloyd aggregation inhibitors.
Figure 6: The most potential β-amiloyd aggregation inhibitors generated by Galante et al. [37].
Scheme 5: Four-component Ugi reaction to obtain FATH hybrids and the best candidate synthesized.
Scheme 6: Four-component Ugi reaction for the synthesis of FATMH hybrids and the best candidate synthesized.
Scheme 7: Petasis multicomponent reaction to produce pyrazine-based MTDLs.
Figure 7: Best pyrazine-based MTDLs synthesized by Madhav et al. [40].
Scheme 8: Synthesis of BCPOs employing a Knoevenagel-based multicomponent reaction and the best candidate syn...
Scheme 9: Hantzsch multicomponent reaction for the synthesis of DHPs as novel MTDLs.
Figure 8: Most active 1,4-dihydropyridines developed by Malek et al. [43].
Scheme 10: Chromone–donepezil hybrid MTDLs obtained via the Passerini reaction.
Figure 9: Best CDH-based MTDLs as AChE inhibitors synthesized by Malek et al. [46].
Scheme 11: Replacement of the nitrogen in lactams 11 with an oxygen in 12 to influence hydrogen-bond donating ...
Scheme 12: MCR 3 + 2 reaction to develop spirooxindole, spiroacenaphthylene, and bisbenzo[b]pyran compounds.
Figure 10: SIRT2 activity of best derivatives obtained by Hasaninejad et al. [49].
Scheme 13: Synthesis of ML192 analogs using the Gewald multicomponent reaction and the best candidate synthesi...
Scheme 14: Development of 1,5-benzodiazepines via Ugi/deprotection/cyclization (UDC) approach by Xu et al. [59].
Scheme 15: Synthesis of polysubstituted 1,4-benzodiazepin-3-ones using UDC strategy.
Scheme 16: Synthetic procedure to obtain 3-carboxamide-1,4-benzodiazepin-5-ones employing Ugi–reduction–cycliz...
Scheme 17: Ugi cross-coupling (U-4CRs) to synthesize triazolobenzodiazepines.
Scheme 18: Azido-Ugi four component reaction cyclization to obtain imidazotetrazolodiazepinones.
Scheme 19: Synthesis of oxazolo- and thiazolo[1,4]benzodiazepine-2,5-diones via Ugi/deprotection/cyclization a...
Scheme 20: General synthesis of 2,3-dichlorophenylpiperazine-derived compounds by the Ugi reaction and Ugi/dep...
Figure 11: Best DRD2 compounds synthesized using a multicomponent strategy.
Scheme 21: Bucherer–Bergs multicomponent reaction to obtain a key intermediate in the synthesis of pomaglumeta...
Scheme 22: Ugi reaction to synthesize racetam derivatives and example of two racetams synthesized by Cioc et a...
Synthesis of pyrrole-fused dibenzoxazepine/dibenzothiazepine/triazolobenzodiazepine derivatives via isocyanide-based multicomponent reactions
- Marzieh Norouzi,
- Mohammad Taghi Nazeri,
- Ahmad Shaabani and
- Behrouz Notash
Beilstein J. Org. Chem. 2024, 20, 2870–2882, doi:10.3762/bjoc.20.241
- diagnostic and therapeutic procedures [25] or PBOX-6 is a drug for the treatment of depression [26]. Benzothiazepines are known as antidepressants and are molecules with interesting electronic properties (Figure 1) [27]. Accordingly, the synthesis of new derivatives of pyrrole-fused benzodiazepine
Graphical Abstract
Figure 1: Representation of distinguished structures of benzodiazepine/benzoxazepine/benzothiazepine with pha...
Scheme 1: Methods for the construction of pyrrole-fused heterocycles through I-MCR reactions.
Scheme 2: The model reaction of dibenzoxazepine, gem-diactivated olefin (2-benzylidenemalononitrile), and cyc...
Scheme 3: Substrate scope. Conditions: Reactions were carried out using 1 (0.55 mmol), 2 (0.55 mmol), and 3 (...
Scheme 4: Substrate scope..Conditions: reactions were carried out using 1 (0.55 mmol), 2 (0.55 mmol), and 5 (...
Figure 2: The crystal structure of 4h (CCDC 2365305).
Figure 3: The DNMR (dynamic nuclear magnetic resonance) spectra of compound 6f (DMSO-d6, 300 MHz) at 25–85 °C...
Figure 4: The crystal structure of 6a (CCDC2365306).
Scheme 5: A suggested mechanism for compounds 4.
Scheme 6: Synthesis of pyrrole-fused dibenzoxazepine/triazolobenzodiazepine through a 4-CR.
Scheme 7: Gram-scale synthesis of pyrrole-fused dibenzoxazepine/triazolobenzodiazepine 4a and 6a via 3-CRs.
Figure 5: UV–vis absorption for compounds 4a, 6c and QS (quinine sulfate) (a); emission for 4a, 6c and QS (b)...
Natural resorcylic lactones derived from alternariol
- Joachim Podlech
Beilstein J. Org. Chem. 2024, 20, 2171–2207, doi:10.3762/bjoc.20.187
- : 87.2 μg/mL) [115]. It furthermore had a negative effect on progesterone synthesis in porcine granulosa cells [100] and selectively inhibited human monoamine oxidase-A (MAO-A) with an IC50 value of 1.71 μM (but did not inhibit MAO-B) and was thus considered for the treatment of depression, Parkinson’s
Graphical Abstract
Figure 1: Examples of compounds covered in this review categorized in six sub-classes (see text).
Figure 2: Examples of compounds not covered in this review.
Figure 3: Wrongly assigned and thus obsolete structures (details will be discussed in the respective chapters...
Figure 4: Alternariol with the correct IUPAC numbering and an occasionally used numbering based on the biphen...
Figure 5: Alternariol O-methyl ethers.
Figure 6: Alternariol O-glycosides.
Figure 7: Alternariol O-acetates and O-sulfates.
Figure 8: 2-Hydroxy- and 4-hydroxy-substituted alternariol and its O-methyl ethers.
Figure 9: Chloro- and amino-substituted alternariol and its O-methyl ethers.
Figure 10: Presumed alternariol derivatives with non-canonical substitution pattern.
Figure 11: Alternariol derivatives with the 1-methyl group hydroxylated.
Figure 12: Verrulactones: pseudo-dimeric derivatives of altertenuol and related compounds.
Figure 13: Biaryls formed by reductive lactone opening and/or by decarboxylation.
Figure 14: Altenuene and its diastereomers.
Figure 15: 9-O-Demethylated altenuene diastereomers.
Figure 16: Acetylated and methylated altenuene diastereomers.
Figure 17: Altenuene diastereomers modified with lactic acid, pyruvic acid, or acetone.
Figure 18: Neoaltenuene and related compounds.
Figure 19: Dehydroaltenusin and its derivatives.
Scheme 1: Equilibrium of dehydroaltenusin in polar solvents [278].
Figure 20: Further quinoid derivatives.
Figure 21: Dehydroaltenuenes.
Figure 22: Complex aggregates containing dehydroaltenuene substructures and related compounds.
Figure 23: Dihydroaltenuenes.
Figure 24: Altenuic acids and related compounds.
Figure 25: Cyclopentane- and cyclopentene-fused derivatives.
Figure 26: Cyclopentenone-fused derivatives.
Figure 27: Spiro-fused derivatives and a related ring-opened derivative.
Figure 28: Lactones-fused and lactone-substituted derivatives.
Scheme 2: Biosynthesis of alternariol [324].
Scheme 3: Biosynthesis of alternariol and its immediate successors with the genes involved in the respective ...
Scheme 4: Presumed formation of altenuene and its diastereomers and of botrallin.
Scheme 5: Presumed formation of altenuic acids and related compounds.
Scheme 6: A selection of plausible biosynthetic paths to cyclopenta-fused metabolites. (No stereochemistry is...
Scheme 7: Biomimetic synthesis of alternariol (1) by Harris and Hay [66].
Scheme 8: Total synthesis of alternariol (1) by Subba Rao et al. using a Diels–Alder approach [34].
Scheme 9: Total synthesis of alternariol (1) using a Suzuki strategy by Koch and Podlech [62], improved by Kim et...
Scheme 10: Total synthesis of alternariol (1) using an intramolecular biaryl coupling by Abe et al. [63].
Scheme 11: Total synthesis of altenuene (54) and isoaltenuene (55) by Podlech et al. [249].
Scheme 12: Total synthesis of neoaltenuene (69) by Podlech et al. [35].
Scheme 13: Total synthesis of TMC-264 (79) by Tatsuta et al. [185].
Scheme 14: Total synthesis of cephalosol (99) by Koert et al. [304].
Synthesis of 2-benzyl N-substituted anilines via imine condensation–isoaromatization of (E)-2-arylidene-3-cyclohexenones and primary amines
- Lu Li,
- Na Li,
- Xiao-Tian Mo,
- Ming-Wei Yuan,
- Lin Jiang and
- Ming-Long Yuan
Beilstein J. Org. Chem. 2024, 20, 1468–1475, doi:10.3762/bjoc.20.130
- ; primary amine; Introduction Aniline derivatives possessing arylmethyl substituents at the ortho position are an important class of amines. They have a wide variety of practical applications, ranging from anti-depression [1], being δ receptor stimulants in analgesic pharmaceuticals [2], to antioxidant
Graphical Abstract
Scheme 1: Synthesis of aniline derivatives from 2-cyclohexenones or derivatives thereof.
Scheme 2: Synthesis of (E)-2-arylidene-3-cyclohexenones 2.
Scheme 3: Substrate scope of (E)-2-arylidene-3-cyclohexenones 2. Conditions: reactions were conducted with 2a...
Scheme 4: Substrate scope of primary amines 3. Conditions: reactions conducted with 2 (0.2 mmol) and 3b–y (2....
Scheme 5: Gram-scale reaction and successive one-pot synthesis.
Scheme 6: Synthetic manipulation.
Synthesis of substituted triazole–pyrazole hybrids using triazenylpyrazole precursors
- Simone Gräßle,
- Laura Holzhauer,
- Nicolai Wippert,
- Olaf Fuhr,
- Martin Nieger,
- Nicole Jung and
- Stefan Bräse
Beilstein J. Org. Chem. 2024, 20, 1396–1404, doi:10.3762/bjoc.20.121
- cholerae [13], show antimicrobial properties [14], and can act as P2X7 antagonists, a receptor involved in neuroinflammation and depression [15]. Pyrazolyltriazoles are most easily obtained via the copper-catalyzed azide–alkyne cycloaddition (CuAAC) from pyrazolyl azides (7 and 8). These are usually
- immobilized building blocks. Biologically active pyrazole–triazole hybrids 1–4: inhibitory effect on cholera bacteria [13], antimicrobial properties [14], P2X7 antagonists (depression) [15] and ERK3 inhibition [12]. Synthesized triazole–pyrazole hybrids 21aa–vg. Literature-reported synthetic routes to
Graphical Abstract
Figure 1: Biologically active pyrazole–triazole hybrids 1–4: inhibitory effect on cholera bacteria [13], antimicr...
Scheme 1: Literature-reported synthetic routes to pyrazole–triazole hybrids: synthesis of azides 7 or 8 from ...
Scheme 2: Synthesis of pyrazolyl azides 19a–v via cleavage of the protecting triazene moiety. For compounds 1...
Scheme 3: Synthesis of pyrazole–triazole hybrids via CuAAC and ORTEP diagrams of triazole products 21sd and 2...
Figure 2: Synthesized triazole–pyrazole hybrids 21aa–vg.
Scheme 4: One-pot synthesis of triazole–pyrazole hybrid 21gd. aOne-pot setup yielded 21gd with unknown impuri...
Scheme 5: Solid-phase synthesis of azidopyrazole 19g and triazole–pyrazole hybrid 21gd by immobilization of a...
Research progress on the pharmacological activity, biosynthetic pathways, and biosynthesis of crocins
- Zhongwei Hua,
- Nan Liu and
- Xiaohui Yan
Beilstein J. Org. Chem. 2024, 20, 741–752, doi:10.3762/bjoc.20.68
- [65][66][67]. Crocins ameliorate depression-like behavior in rats by mitigating neuroinflammation and reducing IL-1β, ROS, and malondialdehyde [10][68]. Tao et al. found that crocins exert an antidepressant effect by enhancing adult hippocampal neurogenesis (AHN) levels and activating the Wnt/β
Graphical Abstract
Figure 1: Principal structure of crocin and crocetin derivatives, including common substituents of the crocet...
Figure 2: The pharmacological activity and mechanisms of action of crocins.
Figure 3: Crocin biosynthetic pathways in C. sativus and G. jasminoides. Enzyme abbreviations are as follows:...
Entry to new spiroheterocycles via tandem Rh(II)-catalyzed O–H insertion/base-promoted cyclization involving diazoarylidene succinimides
- Alexander Yanovich,
- Anastasia Vepreva,
- Ksenia Malkova,
- Grigory Kantin and
- Dmitry Dar’in
Beilstein J. Org. Chem. 2024, 20, 561–569, doi:10.3762/bjoc.20.48
- treatment of acute severe pain) [29] and an investigational drug NOP-1A (a ligand for the nociceptin/orphanin FQ peptide (NOP) receptor which is thought to be involved in several central nervous system disorders such as anxiety, depression, drug abuse, and seizures) [30]. A wide range of biological
Graphical Abstract
Scheme 1: DAS spirocyclizations reported earlier and the synthetic methodology investigated in this work.
Figure 1: Examples of biologically active compounds and natural products based on THF/THP spiro-conjugates wi...
Scheme 2: An initial example on Rh(II)-catalyzed O–H insertion/base-promoted cyclization involving diazo comp...
Scheme 3: Tandem Rh2(esp)2-catalyzed O–H insertion/base-promoted cyclization involving DAS 1 and various prop...
Scheme 4: Tandem Rh2(esp)2-catalyzed O–H insertion/base-promoted cyclization involving DAS 1 and allenic acid...
Scheme 5: Tandem Rh2(esp)2-catalyzed O–H insertion/base-promoted cyclization involving various DAS 1 and 3-br...
Scheme 6: Tandem Rh2(esp)2-catalyzed O–H insertion/base-promoted cyclization involving DAS 1 and 2-(bromometh...
Scheme 7: Examples where a target spirocyclic product was not observed.
Scheme 8: Plausible mechanism of the transformations studied.
Green and sustainable approaches for the Friedel–Crafts reaction between aldehydes and indoles
- Periklis X. Kolagkis,
- Eirini M. Galathri and
- Christoforos G. Kokotos
Beilstein J. Org. Chem. 2024, 20, 379–426, doi:10.3762/bjoc.20.36
Graphical Abstract
Scheme 1: Examples of BIMs used for their medicinal properties.
Scheme 2: Mechanisms for the synthesis of BIMs using protic or Lewis acids as catalysts.
Scheme 3: Synthesis of bis(indolyl)methanes using DBDMH.
Scheme 4: Competition experiments and synthesis of bis(indolyl)methanes using DBDMH.
Scheme 5: Proposed mechanism for formation of BIM of using DBDMH.
Scheme 6: Synthesis of bis(indolyl)methanes using I2.
Scheme 7: General reaction mechanism upon halogen bonding.
Scheme 8: Synthesis of bis(indolyl)methanes using I2, introduced by Ji.
Scheme 9: Synthesis of bis(indolyl)methanes using Br2 in CH3CN.
Scheme 10: Βidentate halogen-bond donors.
Scheme 11: Synthesis of bis(indolyl)methanes using bidentate halogen-bond donor 26.
Scheme 12: Proposed reaction mechanism.
Scheme 13: Synthesis of bis(indolyl)methanes using iodoalkyne as catalyst.
Scheme 14: Proposed reaction mechanism.
Scheme 15: Optimized reaction conditions used by Ramshini.
Scheme 16: Activation of the carbonyl group by HPA/TPI-Fe3O4.
Scheme 17: Synthesis of BIMs in the presence of nanoAg-Pt/SiO2-doped silicate.
Scheme 18: Mechanism of action proposed by Khalafi-Nezhad et al.
Scheme 19: Activation of the carbonyl group by the Cu–isatin Schiff base complex.
Scheme 20: Optimum reaction conditions published by Jain.
Scheme 21: Organocatalytic protocol utilizing nanoparticles introduced by Bankar.
Scheme 22: Activation of the carbonyl group by the AlCl3·6H2O-SDS-SiO2 complex.
Scheme 23: Optimal reaction conditions for the aforementioned nano-Fe3O4 based catalysts.
Scheme 24: Nanocatalytic protocol proposed by Kaur et al.
Scheme 25: Microwave approach introduced by Yuan.
Scheme 26: Microwave approach introduced by Zahran et al.
Scheme 27: Microwave irradiation protocol introduced by Bindu.
Scheme 28: Silica-supported microwave irradiation protocol.
Scheme 29: Proposed mechanism for formation of BIM by Nongkhlaw.
Scheme 30: Microwave-assisted synthesis of BIMs catalyzed by succinic acid.
Scheme 31: Proposed mechanism of action of MMO-4.
Scheme 32: Catalytic approach introduced by Muhammadpoor-Baltork et al.
Scheme 33: Reaction conditions used by Xiao-Ming.
Scheme 34: Ultrasonic irradiation-based protocol published by Saeednia.
Scheme 35: Pyruvic acid-mediated synthesis of BIMs proposed by Thopate.
Scheme 36: Synthesis of BIMs using [bmim]BF4 or [bmim]PF6 ionic liquids.
Scheme 37: Synthesis of BIMs utilizing In(OTf)3 in octylmethylimidazolium hexafluorophosphate as ionic liquid.
Scheme 38: FeCl3·6H2O-catalyzed synthesis of BIMs with use of ionic liquid.
Scheme 39: Synthesis of BIMs utilizing the [hmim]HSO4/EtOH catalytic system.
Scheme 40: Synthesis of BIMs utilizing acidic ionic liquid immobilized on silica gel (ILIS-SO2Cl).
Scheme 41: The [bmim][MeSO4]-catalyzed reaction of indole with various aldehydes.
Scheme 42: The role of [bmim][MeSO4] in catalyzing the reaction of indole with aldehydes.
Scheme 43: Synthesis of BIMs utilizing FeCl3-based ionic liquid ([BTBAC]Cl-FeCl3) as catalyst.
Scheme 44: Synthesis of BIMs using [Msim]Cl at room temperature.
Scheme 45: [Et3NH][H2PO4]-catalyzed synthesis of bis(indolyl)methanes.
Scheme 46: PILs-catalyzed synthesis of bis(indolyl)methanes.
Scheme 47: FSILs-mediated synthesis of bis(indolyl)methanes.
Scheme 48: Possible “release and catch” catalytic process.
Scheme 49: Synthesis of bis(indolyl)methanes by [DABCO-H][HSO4].
Scheme 50: Synthesis of bis(indolyl)methanes by [(THA)(SO4)].
Scheme 51: Synthesis of BBSI-Cl and BBSI-HSO4.
Scheme 52: Synthesis of BIMs in the presence of BBSI-Cl and BBSI-HSO4.
Scheme 53: Chemoselectivity of the present method.
Scheme 54: Synthesis of BIMs catalyzed by chitosan-supported ionic liquid.
Scheme 55: Proposed mechanism of action of CSIL.
Scheme 56: Optimization of the reaction in DESs.
Scheme 57: Synthesis of BIMs using ChCl/SnCl2 as DES.
Scheme 58: Synthesis of BIMs derivatives in presence of DES.
Scheme 59: BIMs synthesis in choline chloride/urea (CC/U).
Scheme 60: Flow chemistry-based synthesis of BIMs by Ley.
Scheme 61: Flow chemistry-based synthesis of BIMs proposed by Nam et al.
Scheme 62: Amino-catalyzed reaction of indole with propionaldehyde.
Scheme 63: Aminocatalytic synthesis of BIMs.
Scheme 64: Proposed mechanism for the aminocatalytic synthesis of BIMs.
Scheme 65: Enzymatic reaction of indole with aldehydes.
Scheme 66: Proposed mechanism for the synthesis of BIMs catalyzed by TLIM.
Scheme 67: Proposed reaction mechanism by Badsara.
Scheme 68: Mechanism proposed by D’Auria.
Scheme 69: Photoinduced thiourea catalysis.
Scheme 70: Proposed mechanism of photoacid activation.
Scheme 71: Proposed mechanism of action for CF3SO2Na.
Scheme 72: Proposed mechanism for the synthesis of BIMs by Mandawad.
Scheme 73: Proposed mechanism for the (a) acid generation and (b) synthesis of BIMs.
Scheme 74: a) Reaction conditions employed by Khaksar and b) activation of the carbonyl group by HFIP.
Scheme 75: Activation of the carbonyl group by the PPy@CH2Br through the formation of a halogen bond.
Scheme 76: Reaction conditions utilized by Mhaldar et al.
Scheme 77: a) Reaction conditions employed by López and b) activation of the carbonyl group by thiourea.
Scheme 78: Infrared irradiation approach introduced by Luna-Mora and his research group.
Scheme 79: Synthesis of BIMs with the use of the Fe–Zn BMOF.
Enantioselective total synthesis of putative dihydrorosefuran, a monoterpene with an unique 2,5-dihydrofuran structure
- Irene Torres-García,
- Josefa L. López-Martínez,
- Rocío López-Domene,
- Manuel Muñoz-Dorado,
- Ignacio Rodríguez-García and
- Miriam Álvarez-Corral
Beilstein J. Org. Chem. 2022, 18, 1264–1269, doi:10.3762/bjoc.18.132
- the perfumery industry [1]. In addition, A. pallens has been used in Indian traditional medicine (Ayurveda) for the treatment of measles, cough, cold, depression, diabetes, and high blood pressure [2]. More recently other biological activities have been reported, such as the blood glucose lowering
Graphical Abstract
Scheme 1: Retrosynthetic scheme of the target molecule 1.
Scheme 2: Synthesis of dihydrofuran-monoterpenoid 1. a) i. O3, −78 °C; ii. PPh3, rt, 76%; b) 1-bromobut-2-yne...
Scheme 3: Racemic resolution of allenol 3 and synthesis of derivatives. a) Lipase AK, vinyl acetate, t-BuOMe,...
On the application of 3d metals for C–H activation toward bioactive compounds: The key step for the synthesis of silver bullets
- Renato L. Carvalho,
- Amanda S. de Miranda,
- Mateus P. Nunes,
- Roberto S. Gomes,
- Guilherme A. M. Jardim and
- Eufrânio N. da Silva Júnior
Beilstein J. Org. Chem. 2021, 17, 1849–1938, doi:10.3762/bjoc.17.126
- against different types of diseases, such as cancer [1][2], malaria [3][4], Chagas disease [5][6], HIV [7][8], depression [9][10], amnesia [11], Alzheimer [12], and maybe even in a more recent scenario, COVID-19 [13]. Even though many compounds are found to present activity against these diseases, only a
- -epoxynaphthalene as electrophiles. Several 2-alkynylbenzamide products were achieved in good yields, including a derivate of moclobemide (42), a drug used to treat depression and anxiety (Scheme 15C) [122]. It is worth mentioning here that this class of molecules can be used as effective anticancer drug carriers
Graphical Abstract
Scheme 1: Schematic overview of transition metals studied in C–H activation processes.
Scheme 2: (A) Known biological activities related to benzimidazole-based compounds; (B and C) an example of a...
Scheme 3: (A) Known biological activities related to quinoline-based compounds; (B and C) an example of a sca...
Scheme 4: (A) Known biological activities related to sulfur-containing compounds; (B and C) an example of a s...
Scheme 5: (A) Known biological activities related to aminoindane derivatives; (B and C) an example of a scand...
Scheme 6: (A) Known biological activities related to norbornane derivatives; (B and C) an example of a scandi...
Scheme 7: (A) Known biological activities related to aniline derivatives; (B and C) an example of a titanium-...
Scheme 8: (A) Known biological activities related to cyclohexylamine derivatives; (B) an example of an intram...
Scheme 9: (A) Known biologically active benzophenone derivatives; (B and C) photocatalytic oxidation of benzy...
Scheme 10: (A) Known bioactive fluorine-containing compounds; (B and C) vanadium-mediated C(sp3)–H fluorinatio...
Scheme 11: (A) Known biologically active Lythraceae alkaloids; (B) synthesis of (±)-decinine (30).
Scheme 12: (A) Synthesis of (R)- and (S)-boehmeriasin (31); (B) synthesis of phenanthroindolizidines by vanadi...
Scheme 13: (A) Known bioactive BINOL derivatives; (B and C) vanadium-mediated oxidative coupling of 2-naphthol...
Scheme 14: (A) Known antiplasmodial imidazopyridazines; (B) practical synthesis of 41.
Scheme 15: (A) Gold-catalyzed drug-release mechanism using 2-alkynylbenzamides; (B and C) chromium-mediated al...
Scheme 16: (A) Examples of anti-inflammatory benzaldehyde derivatives; (B and C) chromium-mediated difunctiona...
Scheme 17: (A and B) Manganese-catalyzed chemoselective intramolecular C(sp3)–H amination; (C) late-stage modi...
Scheme 18: (A and B) Manganese-catalyzed C(sp3)–H amination; (C) late-stage modification of a leelamine deriva...
Scheme 19: (A) Known bioactive compounds containing substituted N-heterocycles; (B and C) manganese-catalyzed ...
Scheme 20: (A) Known indoles that present GPR40 full agonist activity; (B and C) manganese-catalyzed C–H alkyl...
Scheme 21: (A) Examples of known biaryl-containing drugs; (B and C) manganese-catalyzed C–H arylation through ...
Scheme 22: (A) Known zidovudine derivatives with potent anti-HIV properties; (B and C) manganese-catalyzed C–H...
Scheme 23: (A and B) Manganese-catalyzed C–H organic photo-electrosynthesis; (C) late-stage modification.
Scheme 24: (A) Example of a known antibacterial silylated dendrimer; (B and C) manganese-catalyzed C–H silylat...
Scheme 25: (A and B) Fe-based small molecule catalyst applied for selective aliphatic C–H oxidations; (C) late...
Scheme 26: (A) Examples of naturally occurring gracilioethers; (B) the first total synthesis of gracilioether ...
Scheme 27: (A and B) Selective aliphatic C–H oxidation of amino acids; (C) late-stage modification of proline-...
Scheme 28: (A) Examples of Illicium sesquiterpenes; (B) first chemical synthesis of (+)-pseudoanisatin (80) in...
Scheme 29: (A and B) Fe-catalyzed deuteration; (C) late-stage modification of pharmaceuticals.
Scheme 30: (A and B) Biomimetic Fe-catalyzed aerobic oxidation of methylarenes to benzaldehydes (PMHS, polymet...
Scheme 31: (A) Known tetrahydroquinolines with potential biological activities; (B and C) redox-selective Fe c...
Scheme 32: (A) Known drugs containing a benzofuran unit; (B and C) Fe/Cu-catalyzed tandem O-arylation to acces...
Scheme 33: (A) Known azaindolines that act as M4 muscarinic acetylcholine receptor agonists; (B and C) intramo...
Scheme 34: (A) Known indolinones with anticholinesterase activity; (B and C) oxidative C(sp3)–H cross coupling...
Scheme 35: (A and B) Cobalt-catalyzed C–H alkenylation of C-3-peptide-containing indoles; (C) derivatization b...
Scheme 36: (A) Cobalt-Cp*-catalyzed C–H methylation of known drugs; (B and C) scope of the o-methylated deriva...
Scheme 37: (A) Known lasalocid A analogues; (B and C) three-component cobalt-catalyzed C–H bond addition; (D) ...
Scheme 38: (A and B) Cobalt-catalyzed C(sp2)–H amidation of thiostrepton.
Scheme 39: (A) Known 4H-benzo[d][1,3]oxazin-4-one derivatives with hypolipidemic activity; (B and C) cobalt-ca...
Scheme 40: (A and B) Cobalt-catalyzed C–H arylation of pyrrole derivatives; (C) application for the synthesis ...
Scheme 41: (A) Known 2-phenoxypyridine derivatives with potent herbicidal activity; (B and C) cobalt-catalyzed...
Scheme 42: (A) Natural cinnamic acid derivatives; (B and C) cobalt-catalyzed C–H carboxylation of terminal alk...
Scheme 43: (A and B) Cobalt-catalyzed C–H borylation; (C) application to the synthesis of flurbiprofen.
Scheme 44: (A) Benzothiazoles known to present anticonvulsant activities; (B and C) cobalt/ruthenium-catalyzed...
Scheme 45: (A and B) Cobalt-catalyzed oxygenation of methylene groups towards ketone synthesis; (C) synthesis ...
Scheme 46: (A) Known anticancer tetralone derivatives; (B and C) cobalt-catalyzed C–H difluoroalkylation of ar...
Scheme 47: (A and B) Cobalt-catalyzed C–H thiolation; (C) application in the synthesis of quetiapine (153).
Scheme 48: (A) Known benzoxazole derivatives with anticancer, antifungal, and antibacterial activities; (B and...
Scheme 49: (A and B) Cobalt-catalyzed C–H carbonylation of naphthylamides; (C) BET inhibitors 158 and 159 tota...
Scheme 50: (A) Known bioactive pyrrolo[1,2-a]quinoxalin-4(5H)-one derivatives; (B and C) cobalt-catalyzed C–H ...
Scheme 51: (A) Known antibacterial cyclic sulfonamides; (B and C) cobalt-catalyzed C–H amination of propargyli...
Scheme 52: (A and B) Cobalt-catalyzed intramolecular 1,5-C(sp3)–H amination; (C) late-stage functionalization ...
Scheme 53: (A and B) Cobalt-catalyzed C–H/C–H cross-coupling between benzamides and oximes; (C) late-state syn...
Scheme 54: (A) Known anticancer natural isoquinoline derivatives; (B and C) cobalt-catalyzed C(sp2)–H annulati...
Scheme 55: (A) Enantioselective intramolecular nickel-catalyzed C–H activation; (B) bioactive obtained motifs;...
Scheme 56: (A and B) Nickel-catalyzed α-C(sp3)–H arylation of ketones; (C) application of the method using kno...
Scheme 57: (A and B) Nickel-catalyzed C(sp3)–H acylation of pyrrolidine derivatives; (C) exploring the use of ...
Scheme 58: (A) Nickel-catalyzed C(sp3)–H arylation of dioxolane; (B) library of products obtained from biologi...
Scheme 59: (A) Intramolecular enantioselective nickel-catalyzed C–H cycloalkylation; (B) product examples, inc...
Scheme 60: (A and B) Nickel-catalyzed C–H deoxy-arylation of azole derivatives; (C) late-stage functionalizati...
Scheme 61: (A and B) Nickel-catalyzed decarbonylative C–H arylation of azole derivatives; (C) application of t...
Scheme 62: (A and B) Another important example of nickel-catalyzed C–H arylation of azole derivatives; (C) app...
Scheme 63: (A and B) Another notable example of a nickel-catalyzed C–H arylation of azole derivatives; (C) lat...
Scheme 64: (A and B) Nickel-based metalorganic framework (MOF-74-Ni)-catalyzed C–H arylation of azole derivati...
Scheme 65: (A) Known commercially available benzothiophene-based drugs; (B and C) nickel-catalyzed C–H arylati...
Scheme 66: (A) Known natural tetrahydrofuran-containing substances; (B and C) nickel-catalyzed photoredox C(sp3...
Scheme 67: (A and B) Another notable example of a nickel-catalyzed photoredox C(sp3)–H alkylation/arylation; (...
Scheme 68: (A) Electrochemical/nickel-catalyzed C–H alkoxylation; (B) achieved scope, including three using na...
Scheme 69: (A) Enantioselective photoredox/nickel catalyzed C(sp3)–H arylation; (B) achieved scope, including ...
Scheme 70: (A) Known commercially available trifluoromethylated drugs; (B and C) nickel-catalyzed C–H trifluor...
Scheme 71: (A and B) Stereoselective nickel-catalyzed C–H difluoroalkylation; (C) late-stage functionalization...
Scheme 72: (A) Cu-mediated ortho-amination of oxalamides; (B) achieved scope, including derivatives obtained f...
Scheme 73: (A) Electro-oxidative copper-mediated amination of 8-aminoquinoline-derived amides; (B) achieved sc...
Scheme 74: (A and B) Cu(I)-mediated C–H amination with oximes; (C) derivatization using telmisartan (241) as s...
Scheme 75: (A and B) Cu-mediated amination of aryl amides using ammonia; (C) late-stage modification of proben...
Scheme 76: (A and B) Synthesis of purine nucleoside analogues using copper-mediated C(sp2)–H activation.
Scheme 77: (A) Copper-mediated annulation of acrylamide; (B) achieved scope, including the synthesis of the co...
Scheme 78: (A) Known bioactive compounds containing a naphthyl aryl ether motif; (B and C) copper-mediated eth...
Scheme 79: (A and B) Cu-mediated alkylation of N-oxide-heteroarenes; (C) late-stage modification.
Scheme 80: (A) Cu-mediated cross-dehydrogenative coupling of polyfluoroarenes and alkanes; (B) scope from know...
Scheme 81: (A) Known anticancer acrylonitrile compounds; (B and C) Copper-mediated cyanation of unactivated al...
Scheme 82: (A) Cu-mediated radiofluorination of 8-aminoquinoline-derived aryl amides; (B) achieved scope, incl...
Scheme 83: (A) Examples of natural β-carbolines; (B and C) an example of a zinc-catalyzed C–H functionalizatio...
Scheme 84: (A) Examples of anticancer α-aminophosphonic acid derivatives; (B and C) an example of a zinc-catal...
Nanopatterns of arylene–alkynylene squares on graphite: self-sorting and intercalation
- Tristan J. Keller,
- Joshua Bahr,
- Kristin Gratzfeld,
- Nina Schönfelder,
- Marcin A. Majewski,
- Marcin Stępień,
- Sigurd Höger and
- Stefan-S. Jester
Beilstein J. Org. Chem. 2019, 15, 1848–1855, doi:10.3762/bjoc.15.180
- , and lead to blurred regions as marked by arrow 3 in Figure 3a. In addition, nine of the 59 intraannular regions (i.e., 15%) in Figure 3a host a molecule of 2 (up to 17%, see Supporting Information File 1). Eight species of 2 (in Figure 3a) appear as bright features (with a slight central depression
- the procedure described above) a nanopattern of 1a (5 × 10−7 M), and added a 10−4 M solution of 3 in TCB. STM (Figure 4a) shows – again – bright features in the macrocyclic template of 1a. Again, a slight central depression is visible in the STM image which can attributed to the empty center region of
Graphical Abstract
Figure 1: Chemical structures of the molecular squares 1a/b, the kekulene derivative 2, and octulene derivati...
Figure 2: (a)–(c) Scanning tunneling microscopy images, (d)–(f) supramolecular models, and (g)–(l) schematic ...
Figure 3: (a) Overview scanning tunneling microscopy image of a nanopattern of 1a with intermolecularly inter...
Figure 4: (a–c) Scanning tunneling microscopy images of a nanopattern of 1a with intermolecularly intercalate...
A chemically contiguous hapten approach for a heroin–fentanyl vaccine
- Yoshihiro Natori,
- Candy S. Hwang,
- Lucy Lin,
- Lauren C. Smith,
- Bin Zhou and
- Kim D. Janda
Beilstein J. Org. Chem. 2019, 15, 1020–1031, doi:10.3762/bjoc.15.100
- respiratory depression and brain hypoxia [2]. Respiratory depression is a common side effect of opioid overdose and can lead to serious complications, including death. The current treatment for overdose is naloxone (NARCAN®), a competitive antagonist of µ-opioid receptors. Other treatments for opioid
- respiratory depression. Indeed, anti-drug vaccines for individual conjugate vaccines of fentanyl and heroin have already exhibited protection in several animal models [3][4][5][6][7][8]. Antidrug vaccines targeting multiple, structurally distinct species are not common and have utilized two tactics: 1) mixing
Graphical Abstract
Figure 1: Graphical summary of chemically contiguous opioid vaccine approach. A) Illustration of chemically c...
Figure 2: The chemically contiguous heroin–fentanyl haptens designed in this study. Grouping was based on the...
Figure 3: Heroin intermediates used to synthesize HF-1 through HF-9.
Scheme 1: General outline of HF-1, HF-2, HF-3, HF-7 synthesis from fentanyl intermediate 5 and heroin interme...
Scheme 2: Synthesis of fentanyl intermediate 5. Reaction conditions: a) phthalic anhydride, AcOH, reflux, 81%...
Scheme 3: General outline of HF-5, HF-8, HF-9 synthesis from fentanyl intermediates 28 and 46, and heroin int...
Scheme 4: Parallel synthesis of fentanyl domains 25 and 34, for HF-4 and HF-6, respectively.
Scheme 5: General strategy and coupling partners for the chemically contiguous series. aGeneral conditions fo...
Figure 4: Vaccination, titer assessment, and bleed schedule.
Figure 5: Summary of behavioral data for most promising chemically contiguous vaccine HF-7, compared to singu...
Figure 6: Summary of behavioral data for phenethyl-linked haptens HF-4 and HF-6. Bars represent mean ± SEM.
Figure 7: Correlation plots of dual hapten vaccines comparing week 5 and 8 ELISA midpoint titers to ED50 valu...
Asymmetric synthesis of a high added value chiral amine using immobilized ω-transaminases
- Antonella Petri,
- Valeria Colonna and
- Oreste Piccolo
Beilstein J. Org. Chem. 2019, 15, 60–66, doi:10.3762/bjoc.15.6
- intermediates for the synthesis of a large number of biologically active compounds used for the treatment of obesity, type-I and II diabetes mellitus or as psychotropic drugs against depression and schizophrenia [15][16][17][18][19]. In particular (R)-3-amino-1-Boc-piperidine is a useful precursor of compounds
Graphical Abstract
Scheme 1: Transamination reaction of 1-Boc-3-piperidone (1).
Figure 1: Reuse of ATA-025-IMB in five consecutive cycles in the transamination reaction of 1 in batch system...
Figure 2: Reuse of ATA-025-IMB IMB in five consecutive cycles in the transamination reaction of 1 in a flow s...
6’-Fluoro[4.3.0]bicyclo nucleic acid: synthesis, biophysical properties and molecular dynamics simulations
- Sibylle Frei,
- Andrei Istrate and
- Christian J. Leumann
Beilstein J. Org. Chem. 2018, 14, 3088–3097, doi:10.3762/bjoc.14.288
- thymidine unit exhibited a duplex destabilization when paired to DNA (ΔTm/mod = −1.5 to −3.7 °C). The Tm depression was more pronounced for multiple (ΔTm/mod ≈ −3.5 °C) than for single (ΔTm/mod ≈ −2.0 °C) inclusions. When the same four oligonucleotides were hybridized to RNA the duplex stability further
- , the Tm depression was higher with complementary RNA, with pronounced sequence effects in the case of single inclusions. The less destabilizing behaviour of the 6’F-bc4,3-modified oligonucleotides versus complementary DNA suggested that this modification more presents a DNA than a RNA mimic. The better
- effect (−8.5 °C). The Tm depression of the GT-Wobble pair and the CT-mismatch (−11.0 °C) was in the same range than for the natural duplex. However, a lager Tm discrimination was found in the TT-mismatch (−14.1 °C) as in the natural system (−9.7 °C). Taking together, these data suggest that classical
Graphical Abstract
Figure 1: Chemical structure of selected nucleic acid analogs.
Scheme 1: Synthesis of the gem-difluorinated glycal 4 from the silyl enol ethers 1α/β. Reagents and condition...
Scheme 2: Synthesis of the thymidine phosphoramidite building block 10. Reagents and conditions: a) i) thymin...
Scheme 3: Synthesis of the cytidine phosphoramidite building block 16. Reagents and conditions: a) Ac2O, pyri...
Figure 2: Proposed mechanism for the formation of the 5’-phosphorylated fragments during the oxidation step i...
Figure 3: a) Potential energy profile versus pseudorotation phase angle of nucleoside 8 and its two minimal e...
Figure 4: Average structures of the a) 6’F-bc4,3-DNA/DNA, b) 6’F-bc4,3-DNA/RNA, and c) 6’F-bc4,3-DNA/6’F-bc4,3...
Figure 5: Preferred sugar pucker of a) 6’F-bc4,3-DNA/DNA, and b) 6’F-bc4,3-DNA/RNA duplexes and torsion angle...
Novel approach to hydroxy-group-containing porous organic polymers from bisphenol A
- Tao Wang,
- Yan-Chao Zhao,
- Li-Min Zhang,
- Yi Cui,
- Chang-Shan Zhang and
- Bao-Hang Han
Beilstein J. Org. Chem. 2017, 13, 2131–2137, doi:10.3762/bjoc.13.211
- area. As for PPOP-3, using M3 as a monomer may induce a depression of polymerization degree owing to its stereo-hindrance effect, which might be responsible for its lower BET surface area value (880 m2 g−1) and micropore volume (0.20 cm3 g−1) than that of PPOP-2 using M2 as the monomer. However, it is
Graphical Abstract
Scheme 1: Schematic representation of the possible structures of bisphenol-A-based porous organic polymers.
Figure 1: FTIR spectra of terephthalic aldehyde (M1), BPA, and PPOP-1.
Figure 2: Solid-state 13C CP/MAS NMR spectrum of PPOP-1 recorded at the MAS rate of 5 kHz.
Figure 3: (a) Nitrogen adsorption–desorption isotherms of PPOP-1 (downtriangle), PPOP-2 (circle), and PPOP-3 ...
Figure 4: Gravimetric gas adsorption isotherms for PPOP-1 (downtriangle), PPOP-2 (circle), and PPOP-3 (square...
Figure 5: Variation of isosteric heat of adsorption with amount of adsorbed CO2 in PPOP-1, PPOP-2, and PPOP-3....
A strategic approach to [6,6]-bicyclic lactones: application towards the CD fragment of DHβE
- Tue Heesgaard Jepsen,
- Emil Glibstrup,
- François Crestey,
- Anders A. Jensen and
- Jesper Langgaard Kristensen
Beilstein J. Org. Chem. 2017, 13, 988–994, doi:10.3762/bjoc.13.98
- extensively investigated as potential drug targets for a diverse array of central nervous system (CNS) related medical conditions such as Alzheimer’s and Parkinson’s disease, depression, ADHD, pain relief, nicotine addiction and drug abuse [1]. Dihydro-β-erythroidine (DHβE) is a member of the family of
Graphical Abstract
Figure 1: DHβE and related structures. The Ki values of the compounds at the rat α4β2 nAChR subtype determine...
Scheme 1: First strategy towards the CD fragment (Ts-strategy). i) TsCl, TEA, DCM, 0 °C. ii) NaH, DMF, 0 °C, ...
Scheme 2: First strategy towards the CD fragment (Cbz-strategy). i) R-Cl, TEA, CH2Cl2, 0 °C. ii) NaH, DMF, 0 ...
Scheme 3: Second strategy towards the CD fragment. i) 4-Bromobut-1-ene, K2CO3, acetone, 70 °C. ii) n-BuLi, TH...
Figure 2: The binding affinities of compounds 9 and 26 at the rat α4β2 nAChR. a) The AB fragment was evaluate...
Synthesis of 1-indanones with a broad range of biological activity
- Marika Turek,
- Dorota Szczęsna,
- Marek Koprowski and
- Piotr Bałczewski
Beilstein J. Org. Chem. 2017, 13, 451–494, doi:10.3762/bjoc.13.48
Graphical Abstract
Figure 1: Biologically active 1-indanones and their structural analogues.
Figure 2: Number of papers about (a) 1-indanones, (b) synthesis of 1-indanones.
Scheme 1: Synthesis of 1-indanone (2) from hydrocinnamic acid (1).
Scheme 2: Synthesis of 1-indanone (2) from 3-(2-bromophenyl)propionic acid (3).
Scheme 3: Synthesis of 1-indanones 5 from 3-arylpropionic acids 4.
Scheme 4: Synthesis of kinamycin (9a) and methylkinamycin C (9b).
Scheme 5: Synthesis of trifluoromethyl-substituted arylpropionic acids 12, 1-indanones 13 and dihydrocoumarin...
Scheme 6: Synthesis of 1-indanones 16 from benzoic acids 15.
Scheme 7: Synthesis of 1-indanones 18 from arylpropionic and 3-arylacrylic acids 17.
Scheme 8: The NbCl5-induced one-step synthesis of 1-indanones 22.
Scheme 9: Synthesis of biologically active 1-indanone derivatives 26.
Scheme 10: Synthesis of enantiomerically pure indatraline ((−)-29).
Scheme 11: Synthesis of 1-indanone (2) from the acyl chloride 30.
Scheme 12: Synthesis of the mechanism-based inhibitors 33 of coelenterazine.
Scheme 13: Synthesis of the indane 2-imidazole derivative 37.
Scheme 14: Synthesis of fluorinated PAHs 41.
Scheme 15: Synthesis of 1-indanones 43 via transition metal complexes-catalyzed carbonylative cyclization of m...
Scheme 16: Synthesis of 6-methyl-1-indanone (46).
Scheme 17: Synthesis of 1-indanone (2) from ester 48.
Scheme 18: Synthesis of benzopyronaphthoquinone 51 from the spiro-1-indanone 50.
Scheme 19: Synthesis of the selective endothelin A receptor antagonist 55.
Scheme 20: Synthesis of 1-indanones 60 from methyl vinyl ketone (57).
Scheme 21: Synthesis of 1-indanones 64 from diethyl phthalate 61.
Scheme 22: Synthesis of 1-indanone derivatives 66 from various Meldrum’s acids 65.
Scheme 23: Synthesis of halo 1-indanones 69.
Scheme 24: Synthesis of substituted 1-indanones 71.
Scheme 25: Synthesis of spiro- and fused 1-indanones 73 and 74.
Scheme 26: Synthesis of spiro-1,3-indanodiones 77.
Scheme 27: Mechanistic pathway for the NHC-catalyzed Stetter–Aldol–Michael reaction.
Scheme 28: Synthesis of 2-benzylidene-1-indanone derivatives 88a–d.
Scheme 29: Synthesis of 1-indanone derivatives 90a–i.
Scheme 30: Synthesis of 1-indanones 96 from o-bromobenzaldehydes 93 and alkynes 94.
Scheme 31: Synthesis of 3-hydroxy-1-indanones 99.
Scheme 32: Photochemical preparation of 1-indanones 103 from ketones 100.
Scheme 33: Synthesis of chiral 3-aryl-1-indanones 107.
Scheme 34: Photochemical isomerization of 2-methylbenzil 108.
Scheme 35: Synthesis of 2-hydroxy-1-indanones 111a–c.
Scheme 36: Synthesis of 1-indanone derivatives 113 and 114 from η6-1,2-dioxobenzocyclobutene complex 112.
Scheme 37: Synthesis of nakiterpiosin (117).
Scheme 38: Synthesis of 2-alkyl-1-indanones 120.
Scheme 39: Synthesis of fluorine-containing 1-indanone derivatives 123.
Scheme 40: Synthesis of 2-benzylidene and 2-benzyl-1-indanones 126, 127 from the chalcone 124.
Scheme 41: Synthesis of 2-bromo-6-methoxy-3-phenyl-1-indanone (130).
Scheme 42: Synthesis of combretastatin A-4-like indanones 132a–s.
Figure 3: Chemical structures of investigated dienones 133 and synthesized cyclic products 134–137.
Figure 4: Chemical structures of 1-indanones and their heteroatom analogues 138–142.
Scheme 43: Synthesis of 2-phosphorylated and 2-non-phosphorylated 1-indanones 147 and 148 from β-ketophosphona...
Scheme 44: Photochemical synthesis of 1-indanone derivatives 150, 153a, 153b.
Scheme 45: Synthesis of polysubstituted-1-indanones 155, 157.
Scheme 46: Synthesis of 1-indanones 159a–g from α-arylpropargyl alcohols 158 using RhCl(PPh3)3 as a catalyst.
Scheme 47: Synthesis of optically active 1-indanones 162 via the asymmetric Rh-catalyzed isomerization of race...
Scheme 48: Mechanism of the Rh-catalyzed isomerization of α-arylpropargyl alcohols 161 to 1-indanones 162.
Figure 5: Chemical structure of abicoviromycin (168) and its new benzo derivative 169.
Scheme 49: Synthesis of racemic benzoabicoviromycin 172.
Scheme 50: Synthesis of [14C]indene 176.
Scheme 51: Synthesis of indanone derivatives 178–180.
Scheme 52: Synthesis of racemic pterosin A 186.
Scheme 53: Synthesis of trans-2,3-disubstituted 1-indanones 189.
Scheme 54: Synthesis of 3-aryl-1-indanone derivatives 192.
Scheme 55: Synthesis of 1-indanone derivatives 194 from 3-(2-iodoaryl)propanonitriles 193.
Scheme 56: Synthesis of 1-indanones 200–204 by cyclization of aromatic nitriles.
Scheme 57: Synthesis of 1,1’-spirobi[indan-3,3’-dione] derivative 208.
Scheme 58: Total synthesis of atipamezole analogues 211.
Scheme 59: Synthesis of 3-[4-(1-piperidinoethoxy)phenyl]spiro[indene-1,1’-indan]-5,5’-diol hydrochloride 216.
Scheme 60: Synthesis of 3-arylindan-1-ones 219.
Scheme 61: Synthesis of 2-hydroxy-1-indanones 222.
Scheme 62: Synthesis of the 1-indanone 224 from the THP/MOM protected chalcone epoxide 223.
Scheme 63: Synthesis of 1-indanones 227 from γ,δ-epoxy ketones 226.
Scheme 64: Synthesis of 2-hydroxy-2-methylindanone (230).
Scheme 65: Synthesis of 1-indanone derivatives 234 from cyclopropanol derivatives 233.
Scheme 66: Synthesis of substituted 1-indanone derivatives 237.
Scheme 67: Synthesis of 7-methyl substituted 1-indanone 241 from 1,3-pentadiene (238) and 2-cyclopentenone (239...
Scheme 68: Synthesis of disubstituted 1-indanone 246 from the siloxydiene 244 and 2-cyclopentenone 239.
Scheme 69: Synthesis of 5-hydroxy-1-indanone (250) via the Diels–Alder reaction of 1,3-diene 248 with sulfoxid...
Scheme 70: Synthesis of halogenated 1-indanones 253a and 253b.
Scheme 71: Synthesis of 1-indanones 257 and 258 from 2-bromocyclopentenones 254.
Scheme 72: Synthesis of 1-indanone 261 from 2-bromo-4-acetoxy-2-cyclopenten-1-one (260) and 1,2-dihydro-4-viny...
Scheme 73: Synthesis of 1-indanone 265 from 1,2-dihydro-7-methoxy-4-vinylnaphthalene (262) and bromo-substitut...
Scheme 74: Synthesis of 1-indanone 268 from dihydro-3-vinylphenanthrene 266 and 4-acetoxy-2-cyclopenten-1-one (...
Scheme 75: Synthesis of 1-indanone 271 from phenylselenyl-substituted cyclopentenone 268.
Scheme 76: Synthesis of 1-indanone 272 from the trienone 270.
Scheme 77: Synthesis of the 1-indanone 276 from the aldehyde 273.
Scheme 78: Synthesis of 1-indanones 278 and 279.
Scheme 79: Synthesis of 1-indanone 285 from octa-1,7-diyne (282) and cyclopentenone 239.
Scheme 80: Synthesis of benz[f]indan-1-one (287) from cyclopentenone 239 and o-bis(dibromomethyl)benzene (286)....
Scheme 81: Synthesis of 3-methyl-substituted benz[f]indan-1-one 291 from o-bis(dibromomethyl)benzene (286) and...
Scheme 82: Synthesis of benz[f]indan-1-one (295) from the anthracene epidioxide 292.
Scheme 83: Synthesis of 1-indanone 299 from homophthalic anhydride 298 and cyclopentynone 297.
Scheme 84: Synthesis of cyano-substituted 1-indanone derivative 301 from 2-cyanomethylbenzaldehyde (300) and c...
Scheme 85: Synthesis of 1-indanone derivatives 303–305 from ketene dithioacetals 302.
Scheme 86: Synthesis of 1-indanones 309–316.
Scheme 87: Mechanism of the hexadehydro-Diels–Alder (HDDA) reaction.
Scheme 88: Synthesis of 1-indenone 318 and 1-indanones 320 and 321 from tetraynes 317 and 319.
Scheme 89: Synthesis of 1-indanone 320 from the triyn 319.
Scheme 90: Synthesis 1-indanone 328 from 2-methylfuran 324.
Scheme 91: Synthesis of 1-indanones 330 and 331 from furans 329.
Scheme 92: Synthesis of 1-indanone 333 from the cycloadduct 332.
Scheme 93: Synthesis of (S)-3-arylindan-1-ones 335.
Scheme 94: Synthesis of (R)-2-acetoxy-1-indanone 338.
Figure 6: Chemical structures of obtained cyclopenta[α]phenanthrenes 339.
Scheme 95: Synthesis of the benzoindanone 343 from arylacetaldehyde 340 with 1-trimethylsilyloxycyclopentene (...
Comparing blends and blocks: Synthesis of partially fluorinated diblock polythiophene copolymers to investigate the thermal stability of optical and morphological properties
- Pierre Boufflet,
- Sebastian Wood,
- Jessica Wade,
- Zhuping Fei,
- Ji-Seon Kim and
- Martin Heeney
Beilstein J. Org. Chem. 2016, 12, 2150–2163, doi:10.3762/bjoc.12.205
- the block copolymers, where the F-P3OT and P3OT segments are tethered and electronically conjugated this is perhaps less surprising. However the 2:1 blend, which shows evidence of phase separation from the DSC measurements, also exhibits a 20–40 °C depression in the temperature of the Raman transition
Graphical Abstract
Scheme 1: Grignard metathesis polymerization method of synthesizing the diblock copolymer. Relative block len...
Figure 1: Differential scanning calorimetry thermogram (second cycle, 10 K/min) of P3OT-b-F-P3OT 2:1 before (...
Figure 2: Selected region of the 1H NMR (d2-TCE at 403 K) of P3OT-b-F-P3OT produced with 3:1 (a) and 1:3 (b) ...
Figure 3: Thin film UV–visible absorption spectra of 2:1 (a) and 1:4 (b) P3OT-b-F-P3OT polymers (red line), o...
Figure 4: Overlay of thin film UV–visible absorption spectra (a) of the two block copolymers and the correspo...
Figure 5: Thin-film UV–visible absorption spectra of a) P3OT, b) F-P3OT, c) P3OT-b-F-P3OT 2:1, d) P3OT-b-F-P3...
Figure 6: Temperature dependent Raman spectra measured during heating showing the main C–C and C=C stretches ...
Figure 7: Influence of temperature on the relative Raman scattering intensities of the P3OT (1446 cm−1) and F...
cis–trans-Amide isomerism of the 3,4-dehydroproline residue, the ‘unpuckered’ proline
- Vladimir Kubyshkin and
- Nediljko Budisa
Beilstein J. Org. Chem. 2016, 12, 589–593, doi:10.3762/bjoc.12.57
- barriers in Ac-Xaa-OMe. s-cis–s-trans Amide bond isomerism in an N-acyl-proline fragment. The relationship between the pKa of the ammonium function in the amino acid and the amide rotational barrier in proline analogues. The substituents that impose a pKa depression effect should also decrease the content
Graphical Abstract
Scheme 1: s-cis–s-trans Amide bond isomerism in an N-acyl-proline fragment.
Figure 1: Amino acids that have been compared in this study.
Figure 2: X-ray crystal structures of compounds 5–9. Carbon- grey, nitrogen – blue, oxygen – red, fluorine – ...
Scheme 2: The relationship between the pKa of the ammonium function in the amino acid and the amide rotationa...
Figure 3: The double bond between C3 and C4 atoms in 3,4-dehydroproline residues induces an increase in the a...
Synthesis of cyclic N1-pentylinosine phosphate, a new structurally reduced cADPR analogue with calcium-mobilizing activity on PC12 cells
- Ahmed Mahal,
- Stefano D’Errico,
- Nicola Borbone,
- Brunella Pinto,
- Agnese Secondo,
- Valeria Costantino,
- Valentina Tedeschi,
- Giorgia Oliviero,
- Vincenzo Piccialli and
- Gennaro Piccialli
Beilstein J. Org. Chem. 2015, 11, 2689–2695, doi:10.3762/bjoc.11.289
- depolarization. In fact, cADPR induces Ca2+ release from presynaptic and postsynaptic intracellular stores and plays an important role in the activity-dependent synaptic plasticity, including long-term depression [14]. In addition, enzymes able to catalyze the hydrolysis of cyclic ADP-ribose to ADP-ribose are
Graphical Abstract
Figure 1: Structures of cADPR (1), cIDPR (2), cpIDP (3) and cpIMP (4).
Figure 2: Synthetic strategies explored in the cyclization step via phosphodiester bond formation.
Scheme 1: i) (iPr)2NP(OCE)Cl, DIPEA, THF, 1 h, rt; ii) 1) 1H-tetrazole, THF, 2) t-BuOOH, 2 h, rt; iii) 1) (iP...
Scheme 2: i) DNCB, K2CO3, DMF, 4 h, 80 °C; ii) 5-aminopentan-1-ol, DMF, 16 h, 50 °C; iii) Ac2O, pyridine, 2 h...
Figure 3: Effect of 3 and 4 on intracellular [Ca2+] in NGF-differentiated PC12 cells. (A) and (B): representa...
The enantioselective synthesis of (S)-(+)-mianserin and (S)-(+)-epinastine
- Piotr Roszkowski,
- Jan. K. Maurin and
- Zbigniew Czarnocki
Beilstein J. Org. Chem. 2015, 11, 1509–1513, doi:10.3762/bjoc.11.164
- : chiral diamines; enantioselective reduction; epinastine; mianserin; ruthenium complexes; Introduction Mianserin (1) is a tetracyclic compound widely used as a drug in the treatment of depression. Despite the fact that the (S)-(+)-enantiomer of mianserin is more potent than the (R)-antipode in
Graphical Abstract
Figure 1: The structure of mianserin 1 and epinastine 2.
Scheme 1: Enantioselective synthesis of (S)-(+)-mianserin.
Figure 2: Catalysts used in ATH.
Figure 3: The ORTEP diagram for X-ray analysis of compound (S)-7.
Scheme 2: Enantioselective synthesis of (S)-(+)-epinastine.
Synthesis of the furo[2,3-b]chromene ring system of hyperaspindols A and B
- Danielle L. Paterson and
- David Barker
Beilstein J. Org. Chem. 2015, 11, 265–270, doi:10.3762/bjoc.11.29
- hepatitis and depression, and as topical antimicrobials for wounds and snake bites [2][3][4][5]. There is great interest in secondary metabolites produced by plants from the Hypericum genus due to the bioactivity of many compounds that have been isolated from this source. A wide variety of compounds have
Graphical Abstract
Figure 1: Hyperaspidinols A (1) and B (2) and other compounds 3-6 from Hypericum chinense.
Figure 2: Hyperaspidinol A (1), target compound 7 and proposed precursors.
Scheme 1: Reagents and conditions: (i) triethylphosphonoacetate, DBU, THF, 48 h, 94%; (ii) H2, 10% Pd/C, EtOA...
Scheme 2: Reagents and conditions: (i) H3C(CH3O)NH·HCl, n-BuLi, THF, −78 °C, 4 h, 81%; (ii) 1-bromo-3,4-methy...
Figure 3: NOESY correlations in isomers 7a and 7b.
Figure 4: 3D representation of 7a.
Figure 5: 3D representation of 7b.
Figure 6: Possible mechanism for the formation of furo[2,3-b]chromenes 7a and 7b.
The Shono-type electroorganic oxidation of unfunctionalised amides. Carbon–carbon bond formation via electrogenerated N-acyliminium ions
- Alan M. Jones and
- Craig E. Banks
Beilstein J. Org. Chem. 2014, 10, 3056–3072, doi:10.3762/bjoc.10.323
- peptidomimetic of substance P [93]. Substance P is an 11 amino acid peptide that contains a phenylalanine7–phenylalanine8 linkage (Phe7–Phe8) and a member of the mammalian tachykinin family of peptides implicated in diseases such as arthritis, asthma, inflammatory bowel disease and depression. Electrosynthesis
Graphical Abstract
Scheme 1: Application of anodic oxidation to the generation of new carbon-carbon bonds [11].
Scheme 2: The influence of the amino protecting group on the “kinetic” and “thermodynamic” anodic methoxylati...
Scheme 3: Example of the application of the cation pool method [17].
Scheme 4: A thiophenyl electroauxiliary allows for regioselective anodic oxidation [32].
Scheme 5: A diastereoselective cation carbohydroxylation reaction and postulated intermediate 18 [18].
Scheme 6: A radical addition and electron transfer reaction of N-acyliminium ions generated electrosynthetica...
Scheme 7: Catalytic indirect anodic fluorodesulfurization reaction [37].
Figure 1: Schematic of a cation flow system and also shown is the electrochemical microflow reactor reported ...
Figure 2: Example of a parallel laminar flow set-up. Figure redrawn from reference [38].
Figure 3: A catch and release cation pool method [42].
Scheme 8: Micromixing effects on yield 92% vs 36% and ratio of alkylation products [43].
Figure 4: Schematic illustration of the anodic substitution reaction system using acoustic emulsification. Fi...
Scheme 9: Electrooxidation to prepare a chiral oxidation mediator and application to the kinetic resolution o...
Scheme 10: Electrooxidation reactions on 4-membered ring systems [68].
Figure 5: Example of a chiral auxiliary Shono-oxidation intermediate [69].
Scheme 11: An electrochemical multicomponent reaction where a carbon felt anode and platinum cathode were util...
Scheme 12: Preparation of dienes using the Shono oxidation [23].
Scheme 13: Combination of an electroauxiliary mediated anodic oxidation and RCM to afford spirocyclic compound...
Scheme 14: Total synthesis of (+)-myrtine (66) using an electrochemical approach [78].
Scheme 15: Total synthesis of (−)-A58365A (70) and (±)-A58365B (71) [79].
Scheme 16: Anodic oxidation used in the preparation of the poison frog alkaloid 195C [80].
Scheme 17: Preparation of iminosugars using an electrochemical approach [81].
Scheme 18: The electrosynthetic preparation of α-L-fucosidase inhibitors [84,85].
Scheme 19: Enantioselective synthesis of the anaesthetic ropivacaine 85 [71].
Scheme 20: The preparation of synthetically challenging aza-nucleosides employing an electrochemical step [88].
Scheme 21: Synthesis of a bridged tricyclic diproline analogue 93 that induces α-helix conformation into linea...
Scheme 22: Synthesis of (i) a peptidomimetic and (ii) a functionalised peptide from silyl electroauxiliary pre...
Scheme 23: Examples of Phe7–Phe8 mimics prepared using an electrochemical approach [93].
Scheme 24: Preparation of arginine mimics employing an electrooxidation step [96].
Scheme 25: Preparation of chiral cyclic amino acids [20].
Scheme 26: Two-step preparation of Nazlinine 117 using Shono flow electrochemistry [101].
Application of cyclic phosphonamide reagents in the total synthesis of natural products and biologically active molecules
- Thilo Focken and
- Stephen Hanessian
Beilstein J. Org. Chem. 2014, 10, 1848–1877, doi:10.3762/bjoc.10.195
- metabotropic process. There is ongoing interest in mGluRs as drug targets, and the therapeutic potential of mGluR ligands for the treatment of CNS disorders and ailments such as Alzheimer’s and Parkinson’s disease, depression, anxiety, and schizophrenia is being validated [121][122]. The discovery of group II
Graphical Abstract
Figure 1: Examples of phosphonamide reagents used in stereoselective synthesis.
Figure 2: Natural products and bioactive molecules synthesized using phosphonamide-based chemistry (atoms, bo...
Scheme 1: Olefination with cyclic phosphonamide anions, mechanistic rationale, and selected examples 27a–d [18].
Scheme 2: Asymmetric olefination with chiral phosphonamide anions and selected examples 31a–d [1,22].
Scheme 3: Synthesis of α-substituted phosphonic acids 33a–e by asymmetric alkylation of chiral phosphonamide ...
Scheme 4: Asymmetric conjugate additions of C2-symmetric chiral phosphonamide anions to cyclic enones, lacton...
Scheme 5: Asymmetric conjugate additions of P-chiral phosphonamide anions generated from 40a and 44a to cycli...
Scheme 6: Asymmetric cyclopropanation with chiral chloroallyl phosphonamide 47, mechanistic rationale, and se...
Scheme 7: Asymmetric cyclopropanation with chiral chloromethyl phosphonamide 28d [59].
Scheme 8: Stereoselective synthesis of cis-aziridines 57 from chiral chloroallyl phosphonamide 47a [62].
Scheme 9: Synthesis of phosphonamides by (A) Arbuzov reaction, (B) condensation of diamines with phosphonic a...
Figure 3: Original and revised structure of polyoxin A (69) [24-26].
Scheme 10: Synthesis of (E)-polyoximic acid (9) [24-26].
Figure 4: Key assembly strategy of acetoxycrenulide (10) [41,42].
Scheme 11: Total synthesis of (+)-acetoxycrenulide (10) [41,42].
Scheme 12: Synthesis squalene synthase inhibitor 19 by asymmetric sulfuration (A) and asymmetric alkylation (B...
Figure 5: Key assembly strategy of fumonisin B2 (20) and its tricarballylic acid fragment 105 [45,46].
Scheme 13: Final steps of the total synthesis of fumonisin B2 (20) [45,46].
Figure 6: Selected examples of two subclasses of β-lactam antibiotics – carbapenems (111 and 112) and trinems...
Scheme 14: Synthesis of tricyclic β-lactam antibiotic 123 [97].
Scheme 15: Total synthesis of (−)-anthoplalone (8) [56].
Figure 7: Protein tyrosine phosphatase (PTP) inhibitors 130, 131 and model compounds 16, 132 and 133 [68].
Scheme 16: Synthesis of model PTP inhibitors 16a,b [68].
Scheme 17: Synthesis of aziridine hydroxamic acid 17 as MMP inhibitor [63].
Scheme 18: Synthesis of methyl jasmonate (11) [48].
Figure 8: Structures of nudiflosides A (137) and D (13) [49].
Scheme 19: Total synthesis of the pentasubstituted cyclopentane core 159 of nudiflosides A (151) and D (13) an...
Figure 9: L-glutamic acid (161) and constrained analogues [57,124].
Scheme 20: Stereoselective synthesis of DCG-IV (162) [57].
Scheme 21: Stereoselective synthesis of mGluR agonist 21 [124].
Figure 10: Key assembly strategy of berkelic acid (15) [43].
Scheme 22: Total synthesis of berkelic acid (15) [43].
Figure 11: Key assembly strategy of jerangolid A (22) and ambruticin S (14) [27,28].
Scheme 23: Final assembly steps in the total synthesis of jerangolid A [27].
Scheme 24: Key assembly steps in the total synthesis of ambruticin S (14) [28].
Figure 12: General steroid construction strategy based on conjugate addition of 212 to cyclopentenone 48, exem...
Scheme 25: Total synthesis of estrone (12) [44].
